Navigation Links
Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference
Date:10/13/2010

as similar regardless of whether the new agent was a brand or generic anti-epileptic drug.

The company is also presenting two studies on antidepressants. One compares discontinuation rates and healthcare costs between patients starting brand and generic sertraline. Another examines discontinuation rates and costs between patients starting any brand or generic selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs).

Conclusions of the antidepressant studies included that the short-term costs of using brand versus generic sertraline were similar, and the costs of using any generic SSRIs and SNRIs were lower. Both studies found that the risks of discontinuation were similar in patients starting either a brand or generic antidepressant.

Express Scripts researchers are also presenting two additional studies at the conference:

  • An analysis of the effect of message framing on patients' decisions related to cost savings opportunities. In the study, patients who received letters that employed an illusion of progress message frame were more likely to choose to save on prescription costs by switching to a lower-cost alternative drug or moving a prescription from a retail pharmacy to home delivery. The principle of illusion of progress proposes that people behave differently the closer they get to an end goal or reward, and that they will accelerate a particular behavior to reach that point faster.
  • A study of a commercially insured cohort of breast cancer patients, describing the use of filgrastim and pegfilgrastim. These agents are used to improve tolerability of chemotherapy regimens. Researchers found that actual use of these agents often deviated from established treatment guidelines, including a substantial number of patients who received concurrent therapy with both agents. These concurrent users received a lower intensity of treatment, but were on therapy for a significantly longe
    '/>"/>

  • SOURCE Express Scripts, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, The Directors Common Fund to Provide Human Tissue for GTEx, the New Genotype-Tissue Expression Project
    2. Express Scripts Announces Third Quarter 2010 Earnings and 2011 Earnings Guidance Conference Call
    3. Express Scripts Accurately Predicts Which Patients Are Likely to Ignore Doctors Orders
    4. Express Scripts Completes Spinoff of Rx Outreach
    5. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
    6. Express Scripts to Present at Barclays 2010 Global Healthcare Conference
    7. Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
    8. Supelco(R) Introduces Breakthrough in Bioseparations Performance -- Ascentis(R) Express ES-C18 HPLC Columns
    9. Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity
    10. Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced
    11. Help is Here Express in Orlando to Help Floridians Afford Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Therapeutic ... to their offering. This report deals ... aimed at improving patient care by monitoring drug ... dose of drugs for improving outcome. TDM is ...
    (Date:9/2/2015)... , Sept. 2, 2015  ArmaGen, Inc., ... revolutionary therapies to treat severe neurological disorders, announced ... in its multi-center Phase 1/2a clinical trial of ... (MPS I). AGT-181 is an ... of MPS I. The most severe form of ...
    (Date:9/2/2015)... 2, 2015  Boca Raton Regional Hospital,s ... performing ultra-minimally invasive left atrial appendage ligation for ... as Coumadin, Xarelto or Effient. Dr. Cartledge, who ... is one of a select group of surgeons ... microscopic incisions in order to seal off the ...
    Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
    ... ... Preclinical Study -, - RDEA427 Selected as Clinical Candidate, Demonstrated a 40 ... with Potential for Once Daily Oral Dosing -, ... announced preclinical data on its lead non-nucleoside,reverse transcriptase inhibitor (NNRTI) candidate, RDEA806, ...
    ... the Utility of CAPHOSOL in Treating Oral Mucositis, ... show that CAPHOSOL(R), (http://www.caphosol.com ), an advanced electrolyte ... of life for cancer patients undergoing,chemotherapy and radiation ... last week at the 33rd Annual Congress of ...
    Cached Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 2CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 3CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 5CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 6
    (Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
    (Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
    (Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
    Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
    ... BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin ... China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"),has obtained ... that aid in manufacturing blood dialysis. , ... for patents for its core,technology with the State Intellectual ...
    ... HOUSTON, June 26 The Breast Center at Houston Northwest ... the United States -- and one in Texas -- to ... by the National Quality Measures for Breast Centers (NQMBC) Program(TM). ... measure performance of interdisciplinary breast care nationwide. The designation is ...
    ... ... in Omaha list for the second straight year. The list is sponsored by the Greater Omaha ... an Omaha business. , ... June 26, 2009 -- Healthcare staffing company Medical Solutions has landed on the ...
    ... DC (26 June, 2009) Combating high blood pressure ... enjoyed reductions in cardiovascular disease over recent decades, Latin ... published in the journal Therapeutic Advances in Cardiovascular ... the increase in many Latin American countries, a situation ...
    ... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... the Food and Drug Administration, today arrived and seized ... also included ingredients held at these same facilities. The ... in May 2009, found unresolved violations of cGMP requirements ...
    ... Texas, June 25 Torchmark Corporation (NYSE: TMK ... $300 million in aggregate principal amount of 9.25% Senior Notes ... to close on June 30, 2009, subject to the satisfaction ... offering will be used for the repayment of the $99.45 ...
    Cached Medicine News:Health News:RainEarth Obtains Patent Approvals for Its Core Technology 2Health News:RainEarth Obtains Patent Approvals for Its Core Technology 3Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 2Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4Health News:Latin America must cut blood pressure to thrive 2Health News:Latin America must cut blood pressure to thrive 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Torchmark Prices Senior Notes Offering 2
    AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
    Medicine Products: